Yamagata Clinical Helicobacter pylori study group

UMIN ID: UMIN000002087

Registered date:17/06/2009

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: peptic ulcer
• Date of first enrollment: 2000/11/01
• Target sample size: 4000
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

H. pylori eradication therapy consisted of lansoprazole 30 mg or omeprazole 20 mg, plus amoxicillin 750 mg and clarithromycin 200 or 400 mg all twice daily for 7 days.
Conventional antacid therapy consisted of antacids such as proton-pump inhibitors (PPIs) and histamine-H2 blockers for 6 or 8 weeks.

Outcome(s)

• Primary Outcome: Incident rate ratio (IRR) of gastric cancer between patients receiving and not receiving H. pylori eradication therapy until end of 2007.
• Secondary Outcome: The accumulated incidences of gastric cancer in patients with successful and unsuccessful H. pylori eradication

Key inclusion & exclusion criteria

• Age minimum: 12years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Patients with a history of gastric cancer and those in whom endoscopy or biopsy at the time of registration revealed gastric cancer were excluded from the study.

Related Information

• Primary Sponsor: Yamagata Clinical Helicobacter pylori study group
• Source(s) of Monetary Support: none